news
FDA approved 1,171 generic drugs in 2019
The FDA has released a statement on their generic drug approvals in FY 2019, revealing a new record high breaking above last year.
List view / Grid view
Drug Markets
news
Breakthrough therapy for cystic fibrosis approved by FDA
Trikafta is the first approved treatment that is effective for patients 12 years and older with the most common cystic fibrosis mutation.
news
Teva to supply treatment in settlement agreement on Track 1 opioid case
Teva has agreed to supply opioid medication and make a cash payment in a settlement agreement that removes it from the Track 1 opioid litigation.
news
HER2-positive metastatic breast cancer treatment granted Priority Review
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
news
Seven medicines recommended for approval by EMA
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
news
First non-injectable treatment for severe hypoglycaemia recommended
Marketing authorisation in the EU for Baqsimi, the first non-injectable treatment for very low levels of blood sugar, has been recommended by an EMA committee.
news
Osteoarthritis therapeutics market to be worth $10.1bn by 2024, says report
A new report has said the osteoarthritis therapeutics market is estimated to grow due to rapid increase in the geriatric and obese population.
news
First-in-class migraine treatment approved by FDA
Reyvow (lasmiditan), for the treatment of acute migraine, has received approval from the FDA following success in clinical trials.
news
Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
Johnson & Johnson ordered to pay $8bn in Risperdal case
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
news
First US state bans ‘pay-for-delay’ pharma practice
California’s state governor has signed a bill which will stop drug makers from paying generic drug producers to stay off the market.
article
Will the US pass a bill to lower drug prices?
Despite plans to lower drug prices in the US, political divisions have muddied the waters. This article examines the efforts made by those involved and the possibilities of their success.
news
CDMO outsourcing market to reach $36.51bn by 2023
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
news
CMA accuses three pharma companies of illegal market agreement
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
